Search results
Results From The WOW.Com Content Network
By Ludwig Burger and Anirudh Saligrama. (Reuters) -Sanofi vaunted 12 drugs in development with the potential to make more than $1 billion in annual sales, but failed to reverse a recent plunge in ...
Valeant raised its unsolicited offer for Allergan a second time, to $53.3 billion, increasing the cash portion of the bid in an effort to win the backing of the company, with the cash-and-stock portion of the bid valuing each Allergan share at $179.25. 16 2014 Valeant Pharmaceuticals: Allergan, Inc: 49.4 64
LEO – LEO Pharma. LifeScan – LifeScan. Lilly – Eli Lilly and Company Ltd. Lundbeck – Lundbeck Ltd. Martindale Pharma – Martindale Pharmaceuticals - Ltd (Now Ethypharm UK) Mölnlycke – Mölnlycke Health Care Ltd. Mayne – Mayne Pharma plc. McNeil – McNeil Laboratories Ltd. Meda – Meda Pharmaceuticals Ltd.
Marion Merrell Dow and its predecessor Marion Laboratories was a U.S. pharmaceutical company based in Kansas City, Missouri, from 1950 until 1996.. The company specialized in bringing to market drugs that had been discovered but unmarketed by other companies including Cardizem which treats arrhythmias and high blood pressure, Carafate (an ulcer treatment), Gaviscon (an antacid), Seldane (a ...
By Ludwig Burger. (Reuters) -Sanofi stock plunged on Friday, wiping 20 billion euros ($21 billion) off its market value, after it abandoned its 2025 profit target under a plan to list its consumer ...
A platform match. The investment from Sanofi, a small fraction of the company's $46.2 billion annual revenue in 2023, is not so significant. But Sanofi is one of the world's largest vaccine makers ...
Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi. It was the second largest French pharmaceutical company before it was acquired by Hoechst AG of Frankfurt, Germany in 1997, with pharmaceutical operations combined into the Hoechst Marion Roussel (HMR) division in the United States.
Drugmaker Sanofi's consumer healthcare division has attracted interest from private equity funds as the French group prepares to spin out the business, two sources close to the matter told Reuters.